Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II resection of primary colorectal cancer and synchronous liver metastasis after SOX + bevacizumab and adjuvant S-1
jRCTs021180034Phase 2Completed
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tegafur, oxaliplatin and bevacizumab in colorectal cancer (CRC). Primary endpoint: progression free survival. Started Apr 2018; status: completed.
02
Drugs
tegafuroxaliplatinbevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCTs021180034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021180034.